247 related articles for article (PubMed ID: 2709038)
1. Asymmetry of substantia nigra neuronal loss in Parkinson's disease and its relevance to the mechanism of levodopa related motor fluctuations.
Kempster PA; Gibb WR; Stern GM; Lees AJ
J Neurol Neurosurg Psychiatry; 1989 Jan; 52(1):72-6. PubMed ID: 2709038
[TBL] [Abstract][Full Text] [Related]
2. Levodopa peripheral pharmacokinetics and duration of motor response in Parkinson's disease.
Kempster PA; Frankel JP; Bovingdon M; Webster R; Lees AJ; Stern GM
J Neurol Neurosurg Psychiatry; 1989 Jun; 52(6):718-23. PubMed ID: 2501456
[TBL] [Abstract][Full Text] [Related]
3. Motor response to acute dopaminergic challenge with apomorphine and levodopa in Parkinson's disease: implications for the pathogenesis of the on-off phenomenon.
Colosimo C; Merello M; Hughes AJ; Sieradzan K; Lees AJ
J Neurol Neurosurg Psychiatry; 1996 Jun; 60(6):634-7. PubMed ID: 8648329
[TBL] [Abstract][Full Text] [Related]
4. Result of chronic levodopa therapy and its modification by bromocriptine in Parkinson's disease.
Hoehn MM
Acta Neurol Scand; 1985 Feb; 71(2):97-106. PubMed ID: 3984685
[TBL] [Abstract][Full Text] [Related]
5. Levodopa enhances synaptic plasticity in the substantia nigra pars reticulata of Parkinson's disease patients.
Prescott IA; Dostrovsky JO; Moro E; Hodaie M; Lozano AM; Hutchison WD
Brain; 2009 Feb; 132(Pt 2):309-18. PubMed ID: 19050033
[TBL] [Abstract][Full Text] [Related]
6. [11C]DTBZ-PET correlates of levodopa responses in asymmetric Parkinson's disease.
Kumar A; Mann S; Sossi V; Ruth TJ; Stoessl AJ; Schulzer M; Lee CS
Brain; 2003 Dec; 126(Pt 12):2648-55. PubMed ID: 12937076
[TBL] [Abstract][Full Text] [Related]
7. Comparison of motor response to apomorphine and levodopa in Parkinson's disease.
Kempster PA; Frankel JP; Stern GM; Lees AJ
J Neurol Neurosurg Psychiatry; 1990 Nov; 53(11):1004-7. PubMed ID: 2283512
[TBL] [Abstract][Full Text] [Related]
8. Normal substantia nigra patients treated with levodopa - Clinical, therapeutic and pathological observations.
Rajput AH; Rajput ML; Robinson CA; Rajput A
Parkinsonism Relat Disord; 2015 Oct; 21(10):1232-7. PubMed ID: 26372624
[TBL] [Abstract][Full Text] [Related]
9. Comparison of standard carbidopa-levodopa and sustained-release carbidopa-levodopa in Parkinson's disease: pharmacokinetic and quality-of-life measures.
Pahwa R; Lyons K; McGuire D; Silverstein P; Zwiebel F; Robischon M; Koller WC
Mov Disord; 1997 Sep; 12(5):677-81. PubMed ID: 9380047
[TBL] [Abstract][Full Text] [Related]
10. Age influences magnitude but not duration of response to levodopa.
Durso R; Isaac K; Perry L; Saint-Hilaire M; Feldman RG
J Neurol Neurosurg Psychiatry; 1993 Jan; 56(1):65-8. PubMed ID: 8429325
[TBL] [Abstract][Full Text] [Related]
11. Differential progression of motor impairment in levodopa-treated Parkinson's disease.
Goetz CG; Stebbins GT; Blasucci LM
Mov Disord; 2000 May; 15(3):479-84. PubMed ID: 10830412
[TBL] [Abstract][Full Text] [Related]
12. Treatment of Parkinson's disease: problems with a progressing disease.
Rinne UK
J Neural Transm; 1981; 51(1-2):161-74. PubMed ID: 7264627
[TBL] [Abstract][Full Text] [Related]
13. An intermittent, controlled-rate, slow progressive degeneration model of Parkinson's disease: antiparkinson effects of Sinemet and protective effects of methylphenidate.
Fleming SM; Delville Y; Schallert T
Behav Brain Res; 2005 Jan; 156(2):201-13. PubMed ID: 15582106
[TBL] [Abstract][Full Text] [Related]
14. Controlled release levodopa treatment of motor fluctuations in Parkinson's disease.
Juncos JL; Fabbrini G; Mouradian MM; Serrati C; Kask AM; Chase TN
J Neurol Neurosurg Psychiatry; 1987 Feb; 50(2):194-8. PubMed ID: 3572434
[TBL] [Abstract][Full Text] [Related]
15. Improvement of motor fluctuations in patients with Parkinson's disease following treatment with high doses of pergolide and cessation of levodopa.
Schwarz J; Scheidtmann K; Trenkwalder C
Eur Neurol; 1997; 37(4):236-8. PubMed ID: 9208264
[TBL] [Abstract][Full Text] [Related]
16. Parkinson's disease, depression, and the on-off phenomenon.
Friedenberg DL; Cummings JL
Psychosomatics; 1989; 30(1):94-9. PubMed ID: 2913602
[No Abstract] [Full Text] [Related]
17. Low CSF gamma-aminobutyric acid levels in Parkinson's Disease. Effect of levodopa and carbidopa.
Manyam BV
Arch Neurol; 1982 Jul; 39(7):391-2. PubMed ID: 7103767
[TBL] [Abstract][Full Text] [Related]
18. L-dihydroxyphenylalanine and complex I deficiency in Parkinson's disease brain.
Cooper JM; Daniel SE; Marsden CD; Schapira AH
Mov Disord; 1995 May; 10(3):295-7. PubMed ID: 7651446
[TBL] [Abstract][Full Text] [Related]
19. Drug-induced motor complications in dopa-responsive dystonia: implications for the pathogenesis of dyskinesias and motor fluctuations.
de la Fuente-Fernández R
Clin Neuropharmacol; 1999; 22(4):216-9. PubMed ID: 10442251
[TBL] [Abstract][Full Text] [Related]
20. Levodopa consumption reduces dopaminergic receptor responsiveness in Parkinson's disease.
Vaamonde J; Luquin MR; Obeso JA
Clin Neuropharmacol; 1989 Aug; 12(4):271-84. PubMed ID: 2804991
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
